Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Department of Medical Laboratory Science, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
PLoS One. 2022 Aug 8;17(8):e0271895. doi: 10.1371/journal.pone.0271895. eCollection 2022.
Breast cancer is the most frequent and fatal cancer type globally. The fatality rate of breast cancer is mostly due to disease complications like hematological alterations. Therefore, this study aimed to assess the hematological abnormalities before, during, and after the initiation of cancer treatment in breast cancer patients at the University of Gondar comprehensive specialized hospital.
Hematological profiles were collected from 267 breast cancer patients who attended the cancer treatment center from September 2017 to August 2021. A data extraction sheet was used to extract data from the patient's medical chart, including sociodemography, clinical, and hematological profiles. EPI info version 3.5.1 and SPSS Version 25 softwares were used for data entrance and analysis, respectively. Descriptive statistics were summarized using frequency and percentage. The Friedman test followed by a Wilcoxon signed rank test was used to compare the mean difference between the hematological profiles at zero and after the 4th and 8th cycles of treatment.
Of the total participants, 91% were females, and the median age of the study participants was 45 (IQR = 36, 55) years. Red blood cell, white blood cell, and lymphocyte counts, as well as hematocrit and hemoglobin values, were significantly reduced after the initiation of cancer treatment, while the platelet count and red cell distribution width were significantly increased. The prevalence of anemia was 21.7% (95% CI: 16.6, 26.8), 22.7% (95% CI: 17.6, 27.8), and 26.4% (95% CI: 21.3, 31.5) before, during, and after the initiation of cancer treatment, respectively. The prevalence of leukopenia before, during, and after treatment was 9.7%, 18.8%, and 15.1%, respectively. Finally the prevalence of thrombocytopenia was 6.3%, 3.4%, and 8% at before, during, and after treatment, respectively.
This study concluded that many hematological parameters were significantly affected by the breast cancer treatment. Therefore, proper patient follow-up and provide appropriate interventions related to their hematological abnormalities is crucial. It is also important to conduct further prospective studies to confirm the findings of this study.
乳腺癌是全球最常见和最致命的癌症类型。乳腺癌的死亡率主要归因于疾病并发症，如血液学改变。因此，本研究旨在评估在贡德尔大学综合专科医院接受癌症治疗的乳腺癌患者在癌症治疗开始前、期间和之后的血液学异常。
本研究收集了 2017 年 9 月至 2021 年 8 月期间在癌症治疗中心就诊的 267 名乳腺癌患者的血液学特征。使用数据提取表从患者的病历中提取数据，包括社会人口统计学、临床和血液学特征。使用 EPI info 版本 3.5.1 和 SPSS 版本 25 软件分别进行数据输入和分析。使用频率和百分比对描述性统计数据进行总结。使用 Friedman 检验和 Wilcoxon 符号秩检验比较治疗前和第 4 次和第 8 次周期后血液学特征的均值差异。
在总参与者中，91%为女性，研究参与者的中位年龄为 45（IQR=36,55）岁。在开始癌症治疗后，红细胞、白细胞和淋巴细胞计数以及红细胞压积和血红蛋白值显著降低，而血小板计数和红细胞分布宽度显著增加。在癌症治疗开始前、期间和之后，贫血的患病率分别为 21.7%（95%CI：16.6,26.8）、22.7%（95%CI：17.6,27.8）和 26.4%（95%CI：21.3,31.5）。在癌症治疗开始前、期间和之后白细胞减少的患病率分别为 9.7%、18.8%和 15.1%。最后，在癌症治疗开始前、期间和之后血小板减少的患病率分别为 6.3%、3.4%和 8%。
本研究得出结论，许多血液学参数受到乳腺癌治疗的显著影响。因此，对患者进行适当的随访并提供与其血液学异常相关的适当干预措施至关重要。还需要进行进一步的前瞻性研究来证实本研究的发现。
